Intestinal obstruction can be a surgical emergency
Excess visceral fat is linked to serious conditions such as cardiovascular disease, type 2 diabetes, and systemic inflammation
Boldo (3X)
I previously compared Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) (NONOF) in August 2025, discussing how the prior compounding/regulatory headwinds had triggered their painful corrections, worsened by Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects Summary Eli Lilly's GLP-1 portfolio outpaces Novo Nordisk's sluggish performance, supported by the former's superior tolerability, strategic distribution partnerships, expanding US market share, and accelerated revenue growth
Food & Drug Administration (FDA) approved the first commercial GLP-1 medication for the treatment of type 2 diabetes in 2005
Zu den Symptomen knnen belkeit, Erbrechen, Schwindel, Durchfall, Bauchschmerzen, Herzvernderungen, Rhythmusstrungen und mehr gehren
